Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic BK-specific cytotoxic T lymphocytes

Allogeneic cytotoxic T lymphocytes (CTLs) that are specifically reactive to BK virus (BKV), with potential antiviral activity. Upon infusion of allogeneic BK-specific CTLs into immunocompromised patients who were infected with BKV after allogeneic stem cell transplantation, these cells exert a specific CTL response against BKV, thereby killing and eliminating the BKV-infected cells. BKV is a member of the polyomavirus family that may cause mild symptoms in normal, healthy people; however, BKV infection can lead to severe disease in immunocompromised patients.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	allogeneic BK-CTLs allogeneic BK-specific CTLs

allogeneic BK-specific cytotoxic T lymphocytes

Search NCI's Drug Dictionary